Alliances Pay Off as Millennium s Q3 Loss Narrows | GenomeWeb

NEW YORK, Oct. 16 - Millennium Pharmaceuticals on Tuesday reported narrowed third-quarter losses as revenue from strategic alliances nearly doubled. 

The Cambridge, Mass.-based company said its loss from operations narrowed to $9.5 million, or 4 cents a share, from a loss of $31.9 million, or 16 cents, year over year. 

Revenues from alliances grew to $82 million over the current quarter from $44 million over the same period last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.